Drug Search Results
More Filters [+]

CCR-5MAB004

Alternative Names: ccr-5mab004, ccr5mab004, ccr 5mab004
Latest Update: 2013-08-02
Latest Update Note: Clinical Trial Update

Product Description

CCR5 mAb (CCR5mAb004) is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5

Mechanisms of Action: CCR5 Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CCR-5MAB004

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: HIV Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCR5-HV01

P1

Completed

HIV Infections

None

Recent News Events

Date

Type

Title